Lenacapavir

Lenacapavir, a twice-a-year injection for HIV prevention, is being hailed as a breakthrough that could sharply reduce new infections. But attention is turning to whether the drug will reach the people who need it most, with cost and availability in lower-income countries emerging as key concerns among health advocates and commentators.